Home・Stock List・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Closed

1.14 -0.87

Buy Sell

Overview

Share price change

24h

Current

Min

1.1400000000000001

Max

1.19

Key metrics
By Trading Economics
Income	33M 28M
Sales	35M 35M
P/E Sector Avg	3.429 55.725
EPS	0.89
Profit margin	79.717
Employees	27
EBITDA	33M 28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+191.67% upside

Dividends
By Acuity
Next Earnings	12 Nov 2026

Market Stats
By TradingEconomics
Market Cap	12M 38M
Previous open	2.01
Previous close	1.14

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Sept 2026, 23:51 UTC

Australia's Inflation Rate Expected to Rise to 4.1% Amid Global Economic Pressures Ahead of September 30 Release

27 Sept 2026, 23:51 UTC

China's Non-Manufacturing PMI set for release on September 30, with forecasts indicating continued economic contraction at 49.3 amid cautious market sentiment and geopolitical concerns.

27 Sept 2026, 23:51 UTC

Australia's RBA Trimmed Mean CPI YoY data release on September 30, 2026, is crucial for understanding core inflation trends amid global economic uncertainties and potential interest rate impacts.

27 Sept 2026, 23:51 UTC

Australia's Building Permits Expected to Decline 0.9% in August Amid Mixed Trends and Economic Uncertainty

27 Sept 2026, 23:51 UTC

China's NBS Manufacturing PMI Set for Release on September 30, Forecasted at 50.1 Amid Concerns Over Economic Recovery and Global Trade Relations.

27 Sept 2026, 23:41 UTC

Bank of Japan to Release Key Monetary Policy Minutes Amid Optimism and Inflation Concerns on September 27, 2026

27 Sept 2026, 23:41 UTC

U.S. September 2026 Unemployment Rate Release Forecasts Slight Increase to 4.2%, Amid Cautious Market Sentiment and Economic Policy Discussions

27 Sept 2026, 23:41 UTC

U.S. Average Hourly Earnings Expected to Rise 0.3% in September, Influencing Fed's Rate Hike Decisions Amid Inflation Concerns

27 Sept 2026, 23:41 UTC

U.S. Non-Farm Payrolls Expected to Add 100K Jobs in September Amid Cautious Optimism and Potential Market Volatility

27 Sept 2026, 23:41 UTC

U.S. Labor Force Participation Rate Release on October 2, 2026, Expected Amidst Cautious Sentiment and Economic Challenges

27 Sept 2026, 23:41 UTC

US Average Hourly Earnings Report on October 2 Could Signal Fed Rate Hikes Amid Inflation Concerns and Market Volatility.

27 Sept 2026, 23:11 UTC

S&P Global Manufacturing PMI for South Korea Expected to Show Slight Decline Amid Economic Pressures and Resilient Industries

27 Sept 2026, 23:11 UTC

U.S. Home Prices Expected to Rise 2.2% YoY Amidst Stabilizing Market Sentiment Despite Inflation Pressures

27 Sept 2026, 23:11 UTC

Brazil's Industrial Production MoM Data Release on October 2, 2026: Market Anticipates Recovery Amid Ongoing Volatility.

27 Sept 2026, 23:11 UTC

The EUR/CZK is trading roughly flat at the start of the new week, showing little change since Friday's close and reflecting stable performance.

27 Sept 2026, 23:01 UTC

Correlated Moves

Macro News

The Russell 2000 Index is lower, continuing a decline from Friday's close, amid Boeing's software glitch concerns and ongoing U.S.-China tariff discussions.

27 Sept 2026, 23:01 UTC

Correlated Moves

Macro News

The Nasdaq 100 Index is trading modestly lower amid reports of a U.S.-China tariff agreement on $30 billion in goods and geopolitical concerns.

27 Sept 2026, 23:01 UTC

Macro News

The S&P 500 Index is trading lower amid macroeconomic developments, including the upcoming release of the Bank of Japan's July monetary policy minutes.

27 Sept 2026, 23:01 UTC

Correlated Moves

Macro News

Silver prices fell modestly amid discussions on Iran's military readiness and the upcoming release of the Bank of Japan's policy meeting minutes.

27 Sept 2026, 23:01 UTC

Macro News

The AUD/USD is slightly lower as trading resumes, positioned near the lower end of its one-month range amid upcoming Bank of Japan minutes.

27 Sept 2026, 23:01 UTC

Macro News

Oil (WTI) is advancing modestly as tensions in the Middle East escalate, with Iran signaling a potential disruption to global oil supply routes.

27 Sept 2026, 23:01 UTC

Correlated Moves

Macro News

Gold prices fell modestly, continuing a downward trend as geopolitical tensions and expectations of Bank of Japan minutes weigh on the market.

27 Sept 2026, 23:01 UTC

Correlated Moves

Macro News

Platinum prices are declining, continuing a downward trend influenced by silver's drop and geopolitical tensions affecting global energy markets.

27 Sept 2026, 23:01 UTC

Correlated Moves

Macro News

The Dow Jones Index is lower amid mixed U.S. equities, influenced by U.S.-China tariff discussions and geopolitical concerns over Iran.

27 Sept 2026, 23:01 UTC

U.S. Wholesale Inventories Expected to Rise 1.1% in August, Indicating Strong Business Confidence Amid Economic Uncertainties

27 Sept 2026, 23:01 UTC

U.S. GDP Growth Rate for Q2 2026 Forecasted at 1.6% Amid Positive Foreign Investment and Trade Developments Ahead of September Release.

27 Sept 2026, 23:01 UTC

U.S. GDP Price Index QoQ Final for Q2 2026 set to release on September 30, with a forecasted increase of 0.064%, amid positive market sentiment from U.S.-China trade negotiations aimed at reducing tariffs.

27 Sept 2026, 23:01 UTC

PCE Price Index MoM for August 2026 set to release on September 30, with market expecting a 0.4% increase amid fluctuating inflation trends and rising foreign investment in U.S. equities.

27 Sept 2026, 23:01 UTC

Upcoming PCE Price Index Release on September 30, 2026, May Influence U.S. Inflation Trends and Federal Reserve Policy Amid Mixed Market Sentiment.

27 Sept 2026, 23:01 UTC

Personal Income MoM Data for August 2026 Forecasted to Rise by 0.4%, Indicating Cautious Optimism in U.S. Economic Growth Ahead of Release on September 30.

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

191.67% upside

12 Months Forecast

Average 3.5 USD 191.67%

High 4 USD

Low 3 USD

Based on 2 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Actinium Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.